"Quetiapine Fumarate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.
Descriptor ID |
D000069348
|
MeSH Number(s) |
D02.886.680.702.500.500 D03.633.300.276.500
|
Concept/Terms |
Quetiapine Fumarate- Quetiapine Fumarate
- Fumarate, Quetiapine
- Ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-, (E)-2-butenedioate (2:1) (salt)
ICI 204,636- ICI 204,636
- 204,636, ICI
- ICI-204636
- ICI204636
- ICI 204636
- 204636, ICI
Quetiapine- Quetiapine
- 2-(2-(4-dibenzo(b,f)(1,4)thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol
|
Below are MeSH descriptors whose meaning is more general than "Quetiapine Fumarate".
Below are MeSH descriptors whose meaning is more specific than "Quetiapine Fumarate".
This graph shows the total number of publications written about "Quetiapine Fumarate" by people in this website by year, and whether "Quetiapine Fumarate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2009 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2013 | 0 | 2 | 2 |
2017 | 7 | 4 | 11 |
2018 | 3 | 4 | 7 |
2019 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Quetiapine Fumarate" by people in Profiles.
-
Letter to the editor: Quetiapine safety in ICU delirium management among SARS-CoV-2-infected patients. J Psychosom Res. 2021 10; 149:110598.
-
Delirium triggered by COVID-19 vaccine in an elderly patient. Geriatr Gerontol Int. 2021 Jun; 21(6):540.
-
Association of Quetiapine Overuse Letters With Prescribing by Physician Peers of Targeted Recipients: A Secondary Analysis of a Randomized Clinical Trial. JAMA Psychiatry. 2019 10 01; 76(10):1094-1095.
-
Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial. J Am Acad Child Adolesc Psychiatry. 2019 11; 58(11):1062-1078.
-
Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone. Int J Neuropsychopharmacol. 2018 12 01; 21(12):1090-1101.
-
Effect of Peer Comparison Letters for High-Volume Primary Care Prescribers of Quetiapine in Older and Disabled Adults: A Randomized Clinical Trial. JAMA Psychiatry. 2018 10 01; 75(10):1003-1011.
-
The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia. Acta Psychiatr Scand. 2018 11; 138(5):420-431.
-
Baclofen withdrawal hallucinosis. Asian J Psychiatr. 2018 Aug; 36:90-91.
-
Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines. Acta Psychiatr Scand. 2018 09; 138(3):196-222.
-
Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder. JAMA Psychiatry. 2018 04 01; 75(4):347-355.